Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Hermanns

Showing results (121-130 of 184) with videos related to

Pageof 19
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|December 6, 2019
Impact of <sup>68</sup>Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancerDaniela A Ferraro, Helena I Garcia Schüler, Urs J Muehlematter, et al.
The Journal of Urology|September 22, 2021
Factors Associated with Re-Resection in T1 Bladder Cancer: Identifying Patients Who Do Not Receive Guideline-Concordant Care at the Population LevelMarian S Wettstein, Nancy N Baxter, Rinku Sutradhar, et al.
European Urology Focus|November 15, 2022
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic ReviewAnne Neuenschwander, Chiara Lonati, Luca Antonelli, et al.
Translational Oncology|February 8, 2017
Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder CancerEkaterina Olkhov-Mitsel, Andrea J Savio, Ken J Kron, et al.
Urologic Oncology|September 11, 2024
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levelsChristian D Fankhauser, Marian S Wettstein, Ailsa J Christiansen, et al.
The Prostate|December 16, 2021
Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsyBasil Kaufmann, Karim Saba, Tobias S Schmidli, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 16, 2019
<sup>68</sup>Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancerDaniela A Ferraro, Urs J Muehlematter, Helena I Garcia Schüler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomyKarina Dalsgaard Sørensen, Peter Johannes Wild, Ashkan Mortezavi, et al.
BMC Cancer|June 11, 2010
Periostin is up-regulated in high grade and high stage prostate cancerVerena Tischler, Florian R Fritzsche, Peter J Wild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomyAshkan Mortezavi, Thomas Hermanns, Hans-Helge Seifert, et al.
Pageof 19

Showing results (121-130 of 184) with videos related to

Sort By:
Pageof 19
European Journal of Nuclear Medicine and Molecular Imaging|December 6, 2019
Impact of <sup>68</sup>Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancerDaniela A Ferraro, Helena I Garcia Schüler, Urs J Muehlematter, et al.
The Journal of Urology|September 22, 2021
Factors Associated with Re-Resection in T1 Bladder Cancer: Identifying Patients Who Do Not Receive Guideline-Concordant Care at the Population LevelMarian S Wettstein, Nancy N Baxter, Rinku Sutradhar, et al.
European Urology Focus|November 15, 2022
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic ReviewAnne Neuenschwander, Chiara Lonati, Luca Antonelli, et al.
Translational Oncology|February 8, 2017
Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder CancerEkaterina Olkhov-Mitsel, Andrea J Savio, Ken J Kron, et al.
Urologic Oncology|September 11, 2024
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levelsChristian D Fankhauser, Marian S Wettstein, Ailsa J Christiansen, et al.
The Prostate|December 16, 2021
Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsyBasil Kaufmann, Karim Saba, Tobias S Schmidli, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 16, 2019
<sup>68</sup>Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancerDaniela A Ferraro, Urs J Muehlematter, Helena I Garcia Schüler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomyKarina Dalsgaard Sørensen, Peter Johannes Wild, Ashkan Mortezavi, et al.
BMC Cancer|June 11, 2010
Periostin is up-regulated in high grade and high stage prostate cancerVerena Tischler, Florian R Fritzsche, Peter J Wild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomyAshkan Mortezavi, Thomas Hermanns, Hans-Helge Seifert, et al.
Pageof 19